BETA

Mission Statement

MitoChem Therapeutics was founded by Craig Beeson PhD and Bärbel Rohrer PhD to focus on developing treatments to address the effects of mitochondrial dysfunction in neurodegenerative diseases. Dr. Beeson, a medicinal chemist and Professor of Drug Discovery and Biomedical Sciences, and Dr. Rohrer, a neuroscientist and Professor of Ophthalmology, both at Medical University of South Carolina, combined their expertise in mitochondria, neuroscience and chemistry to tackle hard to treat diseases. With funding from Foundation Fighting Blindness and the NIH the company synthesized compounds that demonstrate promise for treating vision loss from retinitis pigmentosa, age-related macular degeneration and glaucoma.

On the web